ClinicalTrials.gg
CompletedNCT02165930Updated Apr 4, 2016

Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers

A Phase 1 interventional study of Oxycodone and Naltrexone in Healthy, sponsored by Pain Therapeutics. Completed at 2 sites in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-04.

Sponsored by Pain Therapeutics · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

To Estimate Bioavailability Of 40 Mg Doses Of Pf-00345439 Formulation K Under Fasting Conditions with 40% Ethanol Compared with Water in Healthy Volunteers

02

Conditions studied

  • Healthy

Keywords

  • Bioavailability
  • oxycodone
  • ethanol interaction
  • healthy volunteers
03

In context

Lead sponsor

Pain Therapeutics is the lead sponsor of 16 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers
  • History of moderate alcohol consumption
  • Total body weight exceeding 64 kg

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of disease.
  • Positive urine drug test
  • History of alcoholism or heavy alcohol consumption
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Treatment A

    Drug: Oxycodone · Drug: Naltrexone

  • Experimental
    Treatment B

    Drug: Oxycodone · Drug: Naltrexone

Interventions

  • One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions

  • Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).

  • One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions

  • Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]

    AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).

    Time frame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48

Secondary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48

  2. Concentration at time 24 hours (C24)

    Time frame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48

  4. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0,0.5,1,2,3,4,5,6,8,10,12,16,24,36,48

07

Study locations

2 sites
  • Pfizer Investigational Site
    Overland Park, Kansas 66211, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66212, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2014
First posted
Jun 18, 2014
Start
Jul 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Last update
Apr 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02165930
Lead sponsor
Pain Therapeutics
Responsible party
Sponsor
First posted
Jun 18, 2014
Start date
Jul 2014
Primary completion
Aug 2014
Completion
Aug 2014
Last update
Apr 4, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion